Another sweetheart deal tarnishes health 'reform'

Late health-care reform negotiations reportedly included a little favor a well-connected drug company. My column reports:

If the Democrats keep pressing their health plan, they will have to persuade the public to swallow another nasty nugget. It's a provision crafted to benefit one well-connected drug company by keeping generic competitors off the market for an additional 4 1/2 years, and it would cost patients and hospitals $1 billion.